Minireviews Open Access
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2021; 27(20): 2576-2585
Published online May 28, 2021. doi: 10.3748/wjg.v27.i20.2576
COVID-19 in normal, diseased and transplanted liver
Alessandro Signorello, Ilaria Lenci, Martina Milana, Giuseppe Grassi, Leonardo Baiocchi
Alessandro Signorello, Ilaria Lenci, Martina Milana, Giuseppe Grassi, Leonardo Baiocchi, Hepatology Unit, Department of Medicine, University of Tor Vergata, Rome 00133, Italy
ORCID number: Alessandro Signorello (0000-0002-3831-7244); Ilaria Lenci (0000-0001-5704-9890); Martina Milana (0000-0003-2027-0481); Giuseppe Grassi (0000-0001-9182-8759); Leonardo Baiocchi (0000-0003-3672-4505).
Author contributions: Signorello A performed acquisition of data, analysis and interpretation, drafting of manuscript, critical revision; Lenci I, Milana M, and Grassi G performed acquisition of data, critical revision; Baiocchi L performed proposal of study, study conception, correction of manuscript, critical revision.
Conflict-of-interest statement: No conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Leonardo Baiocchi, MD, PhD, Associate Professor, Hepatology Unit, Department of Medicine, University of Tor Vergata, Viale Oxford 81, Rome 00133, Italy. baiocchi@uniroma2.it
Received: February 18, 2021
Peer-review started: February 18, 2021
First decision: March 12, 2021
Revised: March 18, 2021
Accepted: May 7, 2021
Article in press: May 7, 2021
Published online: May 28, 2021

Abstract

Starting from December 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has extended in the entire world giving origin to a pandemic. Although the respiratory system is the main apparatus involved by the infection, several other organs may suffer coronavirus disease 2019 (COVID-19)-related injuries. The human tissues expressing angiotensin-converting enzyme 2 (ACE2) are all possible targets of viral damage. In fact myocarditis, meningo-encephalitis, acute kidney injury and other complications have been described with regard to SARS-CoV-2 infection. The liver has a central role in the body homeostasis contributing to detoxification, catabolism and also synthesis of important factor such as plasma proteins. ACE2 is significantly expressed just by cholangiocytes within the liver, however transaminases are increased in more than one third of COVID-19 patients, at hospital admission. The reasons for liver impairment in the course of this infection are not completely clear at present and multiple factors such as: Direct viral effect, release of cytokines, ischemic damage, use of hepatotoxic drugs, sepsis, and others, may contribute to damage. While COVID-19 seems to elicit just a transient alteration of liver function tests in subjects with normal hepatic function, of concern, more severe sequelae are frequently observed in patients with a reduced hepatic reserve. In this review we report data regarding SARS-CoV-2 infection in subjects with normal or diseased liver. In addition the risks of COVID-19 in immunosuppressed patients (either transplanted or suffering for autoimmune liver diseases) are also described.

Key Words: COVID-19, Liver, Non-alcoholic fatty-liver-disease, Cirrhosis, Liver transplant, Angiotensin-converting enzyme 2

Core Tip: Severe acute respiratory syndrome coronavirus 2 infection, starting from December 2019 in China, has now extended in the whole world. While the respiratory system is mainly involved in the infection other organs may be impaired by coronavirus disease 2019 (COVID-19). In this review we report the current finding regarding the liver during this infection. While mild liver effects occur in normal subjects with COVID-19, severe sequelae may be expected in individuals with a reduced hepatic reserve.



INTRODUCTION

Between December 2019 and January 2020, first China and then the rest of the world observed the emergence of a new pathogen, responsible for the recent pandemic still plaguing our planet. On January 5, 2020, the WHO issued a global alert after 44 patients, hospitalized for pneumonia of unknown origin, were reported by Chinese national authorities[1]. On March 11, 2020, the WHO declared the new coronavirus, identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and responsible for the so called coronavirus disease 2019 (COVID-19)[2], to be pandemic. To date (January 2021), the SARS-CoV-2 infection is approaching 100 million cases worldwide, while 2 million related deaths have been reported globally. SARS-CoV-2 is a virus belonging to the genus Betacoronavirus, family Coronaviridae, subgenus Sarbecovirus, discovered at the end of 2019. It is a single-stranded, positive-sense RNA virus with a 50-200 nm diameter. Since it has close genetic similarity with bat coronaviruses, a zoonotic origin has been suggested, based on the transmission from animal to humans. SARS-CoV-2 possesses four structural proteins called the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein binds the virus genome while the S, E, and M proteins contribute in the assembly of the viral envelope[3].

Impairment of respiratory function is the most frequent clinical concern during infection by this new virus; however, other physiological organ systems can be affected. Among these, SARS-CoV-2-induced hepatic changes are gaining interest for their possible relationship with liver and patient outcome.

The liver plays a fundamental role in metabolism and the synthesis of plasma proteins, as well as in the manipulation and detoxification of diet xenobiotics[4]. Several conditions may lead to chronic hepatitis and cirrhosis or hepato-carcinoma, including viral agents, alcohol abuse, metabolic derangements, and others[5]. The patient affected by liver disease is fragile, and his clinical stability is always in perennial equilibrium. Among the direct causes of hepatic decompensation, the detrimental effect of infections, both viral and bacterial, is well known, and in this particular setting, COVID-19 does not seem less important[6]. This review summarizes the effects of SARS-CoV-2 infection in patients with liver disease, as well as in healthy and liver transplanted subjects. Data available on clinical complications and outcomes are also reported.

INTERACTION OF SARS-COV-2 WITH TISSUES

The SARS-CoV-2 molecular pathways employed by the virus to favor host interaction and invasion are of major interest. Several studies have been conducted on this issue, and the majority of evidence converges to identify the angiotensin-converting enzyme 2 (ACE2), a surface peptidase responsible for the regulation of blood pressure, as a key factor. In fact, Zhou et al[7] demonstrated that ACE2 is the main entry route of SARS-CoV-2 within the cell, as also previously observed for the SARS-CoV and HCoV-NL6 viruses[7]. During the previous SARS pandemic in 2003, it was demonstrated that the use of antibodies against ACE2 effectively counteracted viral replication. On the other hand, ACE1 antibodies did not have any effect[8]. The interaction between this new virus and ACE2 has also been investigated in a study conducted by Xu et al[9], where the strong link between the virus and this receptor was confirmed. ACE2 is present in different organs and tissues, such as alveolar type 2 cells of the lung; epithelial cells of the nasal, nasopharyngeal, and oral mucosa; in the smooth muscles of the gastric and colonic mucosa; in enterocytes of the duodenum, jejunum, ileum, and colon; in myocardiocytes; in the cells of the proximal tubule of the kidney; and in cholangiocytes within the liver[10]. From all of the above, it is clear that any tissue expressing ACE2 might be a possible target for SARS-CoV-2, giving rise to different symptoms with a severity that may be a function of the baseline organ reserve. The main organs expressing ACE2 with the corresponding symptoms/complications COVID-19-related, are reported in Figure 1. Although the main clinical expression is represented by a flu-like mild syndrome, a severe bilateral interstitial pneumonia resulting in acute respiratory distress syndrome (ARDS) and requiring intensive care unit (ICU) management is not rare[11]. Other common clinical manifestations comprise: Nausea, vomiting, anorexia, diarrhea (2%-10% of patients), and altered liver function tests[12].

Figure 1
Figure 1 Organs of human body (different from lung and liver) in which angiotensin-converting enzyme 2 was detected, the main site of expression and the possible coronavirus disease 2019 related symptoms/complications are reported in the corresponding columns. COVID-19: Coronavirus disease 2019; ACE2: Angiotensin-converting enzyme 2.
COVID-19 AND THE NORMAL LIVER

One large retrospective study, conducted in the city of New York, enrolled approximately 5700 COVID-19 patients. Liver transaminase levels were assessed at hospital admission. Increased aspartate transaminase (AST) or alanine transaminase (ALT) was found in 58% and 39% of patients, respectively[13]. Disease worsening during in-hospital stay was associated with a further increase of these enzymes. However, the pathogenetic mechanism leading to these alterations remained unclear. In fact, several factors may all have contributed to the liver changes in this heterogeneous group of patients, such as: (1) a direct viral cytopathic effect; (2) the activation of cytokine cascade; (3) the onset of multi-organ failure; (4) a state of disseminated intravascular coagulation; and (5) the use of potentially hepatotoxic drugs (such as remdesivir), among others[12]. As demonstrated by other research, in the course of COVID-19, the increase in liver enzymes is characterized by a preferential AST elevation, thus recalling the picture observed in alcoholic, metabolic, or ischemic liver conditions[14-16]. Abnormal levels of cholestasis markers are seldom observed[17], even if an increased gamma-glutamyltransferase (GGT) level was reported in 50% of patients in one study[18].

Even though SARS-CoV-2 viral particles were described in hepatocytes in two severe cases[19] a direct cytopathic effect does not seem to explain the liver changes since ACE2 is mainly expressed in the biliary tract, within the liver. On the other hand, despite: (1) the presence of the receptor on cholagiocytes; and (2) “in vitro” evidences demonstrating tight junction damage and bile acids transporter impairment in these cells[20]; cholestasis is seldom observed in COVID-19 clinical setting. With regard to liver damage, however, is to underscore that cardiomyopathy with the resulting myocardial dysfunction, is observed in nearly 33% of hospitalized COVID-19 patients. In this context, the onset of circulatory impairment could reasonably explain the biochemical pattern of the alteration of AST, ALT, and GGT, as in the more common picture of congestive liver disease[21-23]. Supporting this view, a postmortem analysis of liver tissue coming from COVID-19 patients denoted a necrotic injury associated with hypoperfusion and congestive changes[19]. Finally, even if liver involvement is not generally regarded as relevant in subjects without a pre-existing liver impairment, the evaluation of hepatic changes during COVID-19 remains difficult in the clinical setting, due to the lack of a clear understanding of this process[24]. In this perspective, bilirubin elevation, even if rarely observed, seems to expose the patient to an increased risk of mechanical ventilation or death in comparison with changes of other liver enzymes[25].

COVID-19 AND PATIENTS WITH NON-CIRRHOTIC, CHRONIC LIVER DISEASE

As stated in the previous paragraph, the alterations of liver function tests in the course of COVID-19 could be the result of different causal events that may act simultaneously. When damage occurs in a subject with an impaired hepatic functional reserve, a more difficult resolution of the clinical picture may be expected. Of more concern is the large United States study including more than 60 million electronic medical records, which also demonstrated that subjects affected by chronic liver diseases (CLD) were more exposed to acquiring COVID-19[26]. In this western research, the prevalence of CLD in COVID-19 patients accounted for 5% of cases, while data coming from China demonstrated a baseline CLD in 2 to 11% of cases[27].

Several conditions may determine a CLD in humans, including those of a metabolic, toxic, viral, or autoimmune nature. Non-alcoholic- (or metabolic-associated-) fatty-liver-disease (NAFLD), a liver condition ranging from simple steatosis to non-alcoholic steatohepatitis and associated with metabolic syndrome, type II diabetes and obesity, has an estimated prevalence of 25% worldwide[28]. Because of its large burden, the role of NAFLD in determining the degree of liver injury in patients with COVID-19 has aroused much interest.

In China, 70 out of 324 COVID-19 patients (21.6%) were diagnosed with hepatic steatosis during radiological investigations by computed tomography. The severity of the clinical picture of COVID-19 was also increased in those with NAFLD[29]. Moreover, in a retrospective study on 76 patients with COVID-19, the presence of NAFLD was associated with the progression of lung impairment, with an odds ratio of 6.4[30]. In another study, NAFLD was again associated with a fourfold increased risk of a severe course of COVID-19[31]. The picture linking NAFLD to a severe outcome of this viral infection was later challenged by a study coming from Qatar[32]. This research, including 320 patients with NAFLD, showed that this metabolic condition was only associated with a worse outcome (increased ICU stay and requirement of mechanical ventilation) when univariate analysis was employed. On the other hand, the main predictor for mortality or a worst outcome at multivariate analysis were age > 50 years and diabetes, respectively. On the basis of the above studies, it is clear why the possible link between NAFLD and severity of COVID-19 remains controversial. Heterogeneity among studies, related to retrospective patient inclusion and classification, do not contribute to a clear picture. A further analysis possibly shed some light on this issue, linking the grade of liver fibrosis in NAFLD, rather than NAFLD by itself, to a worse COVID-19 outcome[33]. In this perspective, it seems that the extent of liver damage might have a more relevant role in comparison with the metabolic derangement observed in these patients.

Alcoholic liver disease (ALD) represents an important cause of hepatic morbidity and mortality worldwide[34]. Despite the fact that clinical data are not available on COVID-19 ALD patients, concern exists for the increased frailty of these subjects during the pandemic. On the other hand, psychological stress and social distancing seem to have increased individual alcoholic beverage consumption in general.

Alcohol abuse disorders frequently facilitate several comorbidities such as viral infections, diabetes or renal failure, all factors that may contribute to an increased risk of a severe course once SARS-CoV-2 infection occurs[35]. Moreover, increased consumption of alcoholic beverages is considered to be a risk factor for the development of respiratory tract infections that may be complicated by the onset of ARDS, one of the main features of severe COVID-19[17]. Also, in the recovery phase after COVID-19, previous alcohol abuse is considered a predisposing factor for the development of pulmonary fibrosis[36]. However, evidence-based indications in the management of ALD COVID-19-infected patients are lacking at present, and further studies are needed to improve our understanding on this issue. For the time being, expert opinion suggests, in general, to avoid the use of steroids in alcoholic hepatitis while concomitant uncontrolled infections are ongoing, because of the lowering effect on patient's immune defenses[37]. In clinical practice, on the other hand, the use of these drugs might be beneficial in the treatment of COVID-19 despite ALD, challenging our before-SARS-CoV-2 beliefs.

Another important challenge concerns the management of patients with autoimmune hepatitis on immunosuppressive therapy. The lack of data from scientific evidence has encouraged an empirical approach based on dose reduction of immunomodulatory therapy in order to prevent the most deleterious effects of COVID-19[38]. However, preliminary data from the city of Bergamo, in Italy, did not support this view since an increased risk was not observed in immunosuppressed patients during the SARS-CoV-2 epidemic. On the other hand, it must be considered that a possible reactivation of autoimmune hepatitis, after immunosuppressive therapy tapering, would probably require high-dose corticosteroids, greatly increasing the risk of infectious complications in these patients[39]. Therefore, current guidelines do not recommend the reduction of immunomodulatory therapy in the absence of SARS-CoV-2 infection; in the case of overt infection, dose adjustment may be pursued in order to increase the white blood cell count[40,41].

Few data are available on other forms of CLD. With regard to HBV, in a Chinese series represented by 105 hepatitis B surface antigen positive patients hospitalized for COVID-19 (1.9% with cirrhosis, 12.4% on antiviral therapy), 14 developed significant liver injury[12]. In these subjects, liver damage was associated with a severe course of infection in nearly 80% of cases. Since the possible prevention or attenuation of COVID-19 should be postulated with the use of antiviral drugs employed for hepatitis B virus (HBV) or hepatitis C virus (HCV), a Spanish study focused on subjects with chronic viral hepatitis following their specific antiviral regimen[42], with 1 out of 341 HCV patients and 8 out 1764 HBV patients developing COVID-19. Although the majority of them (nearly 80%) were hospitalized, no cases of fatal outcome were observed in this group. Finally, is to underscore that extensive use of intravenous steroid therapy to reduce the inflammatory state can lead to significant HBV reactivation. Routine testing for this virus would be wise in COVID-19 severe patients in order to adopt a timely prophylactic treatment[12].

No data are available at present on the impact of COVID-19 in patients with cholestatic CLD, such as primary biliary cholangitis or primary sclerosing cholangitis.

COVID-19 IN PATIENTS WITH CIRRHOSIS OF THE LIVER

Several factors may lead a cirrhotic patient from a compensated to a decompensated clinical condition. Among these, infections play a relevant role, also promoting the occurrence of acute-on-chronic-liver-failure (ACLF)[43,44]. In this perspective, SARS-CoV-2 infection, characterized by an important activation of the cytokine cascade, sepsis, and altered hepatic perfusion, may determine a significant impairment of hepatic reserve in cirrhosis[6]. Some studies evaluated the clinical outcome of COVID-19 in patients with liver cirrhosis. Preliminary data coming from two international registries and including 103 cirrhotic COVID-19 positive patients demonstrated an increased mortality, in comparison with the general population[45]. Moreover, increased fatality was strictly related to the degree of pre-existing liver impairment; in fact, more than 60% of Child-Pugh C patients died in this study. In the APCOLIS study, a worst COVID-19 outcome in cirrhotic patients was again confirmed[46]. In this research, 43 cirrhotic patients exhibited: (1) increased need of ICU care; (2) more liver–related complication; and (3) enhanced mortality in comparison with non-cirrhotic CLD patients. COVID-19 determined the onset of liver decompensation or ACLF in one out of five patients with cirrhosis. A Child Pugh score > 9 was a significant predictor of mortality.

A study conducted in Italy compared the 30-d in-hospital mortality in a group of patients admitted for COVID-19 infection with or without liver cirrhosis. The all-cause mortality rate was found to be significantly higher in cirrhotic patients with a model for end-stage liver disease score ≥ 15. In addition, this research also evidenced a deterioration of liver function in patients with a long-standing stable liver disease. In fact, a worsening of the Child-Pugh score was observed, from grade A at admission to status B/C during the hospital stay[47]. The mortality rate induced by COVID-19 in patients with decompensated cirrhosis was increased in comparison with other infective causes. In Figure 2, the main postulated mechanisms of liver injury, during COVID-19, are reported, together with the possible outcome as a function of previous liver condition. Finally, cirrhotic patients with hepatocarcinoma (HCC) deserve a separate consideration since neoplastic patients, in general, may have an additional immunologic impairment related to cancer and/or chemotherapy. A national study performed in China on 1590 patients in 575 hospitals showed that patients with an underlying malignancy had a higher risk of SARS-CoV-2 infection than the general population. Obviously, many patients with HCC had an underlying liver impairment that placed them in this higher risk group, with a decidedly more inauspicious clinical outcome[48]. Considering this increased risk, the America Association for Study on Liver Disease (AASLD) and the European Association for the Study of Liver (EASL) recommend a prolongation of the time of clinical and ultrasound surveillance of cirrhotic patients so as not to expose them to possible contagion in the places of treatment, deferring locoregional treatment for HCC where possible in patients with a relatively stable disease, and reserving interventions for patients in which the benefit outweighs the risk of acquiring SARS-CoV-2 infection[40,41]. However, the relationship between an impairment of the immune system (for cancer, immunological diseases, or transplant) and a worse COVID-19 outcome is not demonstrated as yet, as will be reported in details in the following paragraph.

Figure 2
Figure 2 The putative mechanisms inducing liver injury in the course of coronavirus disease 2019 are reported in the left side of the figure (? = controversial data on the specific mechanism). The right part describes the possible outcome according to patient baseline liver condition. NAFLD: Non-alcoholic fatty-liver-disease; COVID-19: Coronavirus disease 2019.
COVID-19 IN LIVER TRANSPLANTED PATIENTS

As there is an assumption that the integrity of the immune-system is an important factor for preventing the most severe sequelae of COVID-19, since the pandemic began, concern has been raised about the possible outcome in liver transplant (LT) patients under continuous immunosuppressive regimen. However, current data do not confirm this worrisome view. An early pediatric analysis coming from the North of Italy (an area badly beaten by the pandemic) demonstrated just three children infected by COVID-19, and with an uneventful outcome, among those liver transplanted or under chemotherapy[39]. Data on adult LT recipients coming from the same geographic area gave a different picture[49]. Three patients having a LT more than ten years before, and with COVID-19, died from complications. All had metabolic impairment (diabetes, hypertension) and were > 65 years. Paradoxically, their immunosuppressive regimen was minimal in comparison with patients with a shorter transplant history, suggesting a possible protective rather detrimental effect of immunosuppression. A large series was published, gathering the data from two international registries (COVID-Hep and SECURE-Cirrhosis)[50]. In this study, data coming from 151 liver transplanted patients were compared with those of 627 controls. The main factors associated with death at multivariate analysis were: Age, creatinine levels, and non-liver malignancy. LT and immunosuppressive regimen were not associated to an increased risk of fatality. Finally, patients with LT required invasive ventilation more frequently (20% LT vs 5% control; P < 0.001), while the overall mortality was increased in the non LT control group (19% LT vs 27% control; P = 0.05). A Spanish prospective study reassessed this issue in 111 LT patients with COVID-19[51]. Although the fatality rate was slightly lower in LT patients, mycophenolate use (especially at > 1 g/daily dose) was associated with an increased risk of severe COVID-19 disease. From these findings, the authors suggested a possible benefit in mycophenolate tapering in COVID-19 LT patients, while a complete drug withdrawal was discouraged. Taken together, the available data do not suggest an increased fatality in LT patients with COVID-19; however, enhanced surveillance would be wise in these subjects because of the increased morbidity reported by some studies. While a possible detrimental effect has been suggested for mycophenolate, a clear picture of the relationship between immunosuppression and COVID-19 severity is still lacking.

CONCLUSION

The effects of COVID-19 on liver health are complex and largely dependent on the underling functional hepatic reserve. The reasons for the elevation of liver enzymes in a significant number of COVID-19 patients, is not clear at present. As a general rule, the effect of COVID-19 seems negligible on the normal liver, but concern exists for patients with impaired liver function. Expert societies, such as AASLD or EASL, are making a great effort to give indications on issues such as LT and the clinical management of liver disease patients during the SARS-CoV-2 pandemic, also in the lack of definitive evidence. While this scenario is quickly evolving, also for the possible emergence of some variant of concern[52] ,other issues are rising for patients with liver disease. Among the pandemic-associated and non-COVID-19-related adverse effects, the reduction of health resources for patients with liver disease may significantly impact their morbidity and mortality. A study in Italy evidenced that there was already a 25% reduction of transplant activity related to an increased ICUs saturation in the first 4 wk of the national pandemic[53]. Abrupt interruption of HCC surveillance in the majority of patients with liver cirrhosis will also have a cost in the future. Finally, a recent study modeling a one year delay in HCV cure since the pandemic estimated an increase of more than 100 thousand in liver related deaths and cancers in the population affected by this virus in the coming years[54]. In conclusion, while hepatologists are presently working in an emergency environment full of uncertainties and with limited resources, an “in search of lost time” attitude will probably be pursued by the same physicians in the future, when the pandemic ends.

Footnotes

Manuscript source: Invited manuscript

Corresponding Author's Membership in Professional Societies: Società Italiana Di Gastroenterologia Ed Endoscopia Digestiva, No. 0013478.

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Italy

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Bain V, Sempokuya T S-Editor: Fan JR L-Editor: A P-Editor: Liu JH

References
1.  Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, Ciccozzi M. COVID-19 Outbreak: An Overview. Chemotherapy. 2019;64:215-223.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 58]  [Article Influence: 78.0]  [Reference Citation Analysis (0)]
2.  Acuti Martellucci C, Flacco ME, Cappadona R, Bravi F, Mantovani L, Manzoli L. SARS-CoV-2 pandemic: An overview. Adv Biol Regul. 2020;77:100736.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 12]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
3.  Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8908]  [Cited by in F6Publishing: 5388]  [Article Influence: 8908.0]  [Reference Citation Analysis (0)]
4.  Glaser T, Baiocchi L, Zhou T, Francis H, Lenci I, Grassi G, Kennedy L, Liangpunsakul S, Glaser S, Alpini G, Meng F. Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. J Cell Mol Med. 2020;24:5955-5965.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 6]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
5.  Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099-2108.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 592]  [Cited by in F6Publishing: 515]  [Article Influence: 84.6]  [Reference Citation Analysis (0)]
6.  Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:727-738.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 177]  [Cited by in F6Publishing: 156]  [Article Influence: 17.7]  [Reference Citation Analysis (0)]
7.  Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8787]  [Cited by in F6Publishing: 6798]  [Article Influence: 8787.0]  [Reference Citation Analysis (0)]
8.  Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3235]  [Cited by in F6Publishing: 2719]  [Article Influence: 179.7]  [Reference Citation Analysis (0)]
9.  Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457-460.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 951]  [Cited by in F6Publishing: 776]  [Article Influence: 951.0]  [Reference Citation Analysis (0)]
10.  Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185-192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 889]  [Cited by in F6Publishing: 789]  [Article Influence: 889.0]  [Reference Citation Analysis (0)]
11.  Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7513]  [Cited by in F6Publishing: 5859]  [Article Influence: 7513.0]  [Reference Citation Analysis (0)]
12.  Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73:1231-1240.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 122]  [Cited by in F6Publishing: 98]  [Article Influence: 122.0]  [Reference Citation Analysis (0)]
13.  Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW;  the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052-2059.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3797]  [Cited by in F6Publishing: 3134]  [Article Influence: 3797.0]  [Reference Citation Analysis (0)]
14.  Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS;  China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-1720.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12133]  [Cited by in F6Publishing: 6929]  [Article Influence: 12133.0]  [Reference Citation Analysis (0)]
15.  Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998-1004.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 379]  [Cited by in F6Publishing: 308]  [Article Influence: 379.0]  [Reference Citation Analysis (0)]
16.  Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266-1271.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 628]  [Cited by in F6Publishing: 215]  [Article Influence: 29.9]  [Reference Citation Analysis (0)]
17.  Schaefer EAK, Arvind A, Bloom PP, Chung RT. Interrelationship Between Coronavirus Infection and Liver Disease. Clin Liver Dis (Hoboken). 2020;15:175-180.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 13]  [Article Influence: 23.0]  [Reference Citation Analysis (0)]
18.  Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73:566-574.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 265]  [Cited by in F6Publishing: 234]  [Article Influence: 265.0]  [Reference Citation Analysis (0)]
19.  Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, Najafian B, Deutsch G, Lacy JM, Williams T, Yarid N, Marshall DA. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet. 2020;396:320-332.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 284]  [Cited by in F6Publishing: 172]  [Article Influence: 284.0]  [Reference Citation Analysis (0)]
20.  Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, Lv T, Liang J, Zhang Q, Xu W, Xie Y, Wang X, Yuan Z, Zhang R, Lin X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020;11:771-775.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 108]  [Article Influence: 100.0]  [Reference Citation Analysis (0)]
21.  Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323:1612-1614.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1103]  [Cited by in F6Publishing: 954]  [Article Influence: 1103.0]  [Reference Citation Analysis (0)]
22.  van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16:84-90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 119]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
23.  Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis. 2011;15:1-20.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 21]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
24.  Moon AM, Barritt AS 4th. Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Dig Dis Sci. 2020;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 2]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
25.  Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology. 2020;72:1169-1176.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 48]  [Article Influence: 62.0]  [Reference Citation Analysis (0)]
26.  Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26:30-39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 65]  [Cited by in F6Publishing: 57]  [Article Influence: 65.0]  [Reference Citation Analysis (0)]
27.  Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-430.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 796]  [Cited by in F6Publishing: 485]  [Article Influence: 796.0]  [Reference Citation Analysis (1)]
28.  Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175-1183.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 119]  [Cited by in F6Publishing: 96]  [Article Influence: 119.0]  [Reference Citation Analysis (0)]
29.  Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, Guo HY, Liu Y, Ling Y, Zhang XY, Wang JF, Lu HZ. [Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area]. Zhonghua Gan Zang Bing Za Zhi. 2020;28:229-233.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 13]  [Reference Citation Analysis (0)]
30.  Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73:451-453.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 191]  [Cited by in F6Publishing: 164]  [Article Influence: 191.0]  [Reference Citation Analysis (0)]
31.  Zhou YJ, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40:2160-2163.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 24]  [Article Influence: 28.0]  [Reference Citation Analysis (0)]
32.  Mushtaq K, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, Iqbal P, Elfert K, Balaraju G, Almaslamani M, Al-Ejji K, AlKaabi S, Kamel YM. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. J Hepatol. 2021;74:482-484.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 9]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
33.  Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545-1547.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 55]  [Article Influence: 54.0]  [Reference Citation Analysis (0)]
34.  Da BL, Im GY, Schiano TD. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease. Hepatology. 2020;72:1102-1108.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 61]  [Article Influence: 57.0]  [Reference Citation Analysis (0)]
35.  Ahmed MZ, Ahmed O, Aibao Z, Hanbin S, Siyu L, Ahmad A. Epidemic of COVID-19 in China and associated Psychological Problems. Asian J Psychiatr. 2020;51:102092.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 334]  [Cited by in F6Publishing: 232]  [Article Influence: 334.0]  [Reference Citation Analysis (0)]
36.  Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med. 2020;2020:6175964.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 40]  [Article Influence: 47.0]  [Reference Citation Analysis (0)]
37.  Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306-333.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 86]  [Article Influence: 117.0]  [Reference Citation Analysis (0)]
38.  Lleo A, Invernizzi P, Lohse AW, Aghemo A, Carbone M. Management of patients with autoimmune liver disease during COVID-19 pandemic. J Hepatol. 2020;73:453-455.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 31]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
39.  D'Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020;26:832-834.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 394]  [Cited by in F6Publishing: 327]  [Article Influence: 394.0]  [Reference Citation Analysis (0)]
40.  Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287-304.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 164]  [Cited by in F6Publishing: 179]  [Article Influence: 164.0]  [Reference Citation Analysis (0)]
41.  Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 203]  [Cited by in F6Publishing: 184]  [Article Influence: 203.0]  [Reference Citation Analysis (1)]
42.  Lens S, Miquel M, Mateos-Muñoz B, García-Samaniego J, Forns X. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol. 2020;73:1262-1263.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 6]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
43.  Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310-1324.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 464]  [Cited by in F6Publishing: 388]  [Article Influence: 66.3]  [Reference Citation Analysis (0)]
44.  Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. N Engl J Med. 2020;382:2137-2145.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 18]  [Article Influence: 72.0]  [Reference Citation Analysis (0)]
45.  Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73:705-708.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 82]  [Article Influence: 97.0]  [Reference Citation Analysis (0)]
46.  Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M;  APASL COVID Task Force; APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14:690-700.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 51]  [Article Influence: 59.0]  [Reference Citation Analysis (0)]
47.  Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063-1071.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 93]  [Cited by in F6Publishing: 89]  [Article Influence: 93.0]  [Reference Citation Analysis (0)]
48.  Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335-337.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2034]  [Cited by in F6Publishing: 1241]  [Article Influence: 2034.0]  [Reference Citation Analysis (0)]
49.  Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5:532-533.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 148]  [Cited by in F6Publishing: 87]  [Article Influence: 148.0]  [Reference Citation Analysis (0)]
50.  Webb GJ, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, Catana MA, Cargill T, Dhanasekaran R, García-Juárez I, Hagström H, Kennedy JM, Marshall A, Masson S, Mercer CJ, Perumalswami PV, Ruiz I, Thaker S, Ufere NN, Barnes E, Barritt AS 4th, Moon AM. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:1008-1016.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 34]  [Article Influence: 77.0]  [Reference Citation Analysis (0)]
51.  Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Nogueras F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148-155.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 64]  [Article Influence: 76.0]  [Reference Citation Analysis (0)]
52.  Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:95-99.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 220]  [Cited by in F6Publishing: 137]  [Article Influence: 220.0]  [Reference Citation Analysis (0)]
53.  Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs. Am J Transplant. 2020;20:1780-1784.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 74]  [Cited by in F6Publishing: 66]  [Article Influence: 74.0]  [Reference Citation Analysis (0)]
54.  Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31-36.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 31]  [Article Influence: 37.0]  [Reference Citation Analysis (0)]